Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells

Clinical and molecular hepatology

Volumn 21, Issue 1, 2015, Pages 49-59

  Gu, Ha R a ^a   Park, Su C heol ^a   Choi, Su J in ^a   Lee, Jae C heol ^a   Kim, You C heoul ^a   Han, Chul J u ^a   Kim, Jin ^a   Yang, Ki Y oung ^a   Kim, Yeon J oo ^a   Noh, Geum Y oub ^a   No, So H yeon ^a   Jeong, Jae Hoon ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

Gefitinib; Hepatocellular carcinoma; Silibinin; Sorafenib

Indexed keywords

ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; NICOTINAMIDE; PROTEIN KINASE B; QUINAZOLINE DERIVATIVE; SILIBININ; SILYMARIN; SORAFENIB;

ANALOGS AND DERIVATIVES; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SILYMARIN;

EID: 85050578196     PISSN: None     EISSN: 2287285X     Source Type: Journal    
DOI: 10.3350/cmh.2015.21.1.49     Document Type: Article

References (0)